Lilly Launches Mounjaro® (tirzepatide) in India for Obesity and Type 2 Diabetes Treatment
Mumbai: Eli Lilly and Company (India) has launched Mounjaro® (tirzepatide), a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes, following marketing authorization from the Central Drugs Standard Control Organization (CDSCO).
Mounjaro® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity or overweight with at least one weight-related comorbid condition. It is also indicated for improving glycemic control in adults with type 2 diabetes mellitus.
In the SURMOUNT-1 trial, adults with obesity or excess weight and weight-related medical problems not including diabetes, experienced substantial weight loss with Mounjaro®. At the highest dose (15 mg), participants lost an average of 21.8 kg over 72 weeks, while those on the lowest dose (5 mg) lost an average of 15.4 kg.
In the SURPASS program, Mounjaro® demonstrated superior A1C reductions versus comparators, with participants achieving average A1C reductions of up to 2.4% over 40 weeks.
Winselow Tucker, President and General Manager, Lilly India, stated, “The dual burden of obesity and type 2 diabetes is a major public health challenge in India. We are committed to collaborating with the government and industry to promote awareness and improve prevention and management of these diseases.”
Dr. Manish Mistry, Senior Medical Director, Lilly India, added, “Mounjaro® may offer a new approach to metabolic health management, providing healthcare providers with an innovative option to treat these diseases.”
